Onzetra Xsail (Sumatriptan Succinate) Patent Expiration, LOE Window & CMS Spending

Onzetra Xsail (Sumatriptan Succinate) by Currax Pharmace: FDA Orange Book LOE 2034-10-20, 16 AB generics, $458K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCurrax Pharmace
FDA Application & PathwayN206099 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-10-20
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$458K
2024 Medicare Part D Spend$458K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel